Overall incidence of myopericarditis does not differ significantly for those receiving COVID-19 vaccines versus non-COVID-19 vaccines<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, April 12, 2022 (HealthDay News) — Myopericarditis is rare following COVID-19 vaccination, with an overall incidence not differing significantly for those receiving COVID-19 vaccines or non-COVID-19 vaccines, according to a review published online April 11 in The Lancet Respiratory Medicine<\/em>.<\/p>\n Ryan Ruiyang Ling, from the Yong Loo Lin School of Medicine in Singapore, and colleagues conducted a systematic review and meta-analysis to examine the incidence of myocarditis following vaccination. Data were included from 22 studies, with 405,272,721 vaccine doses.<\/p>\n The researchers found that the overall incidence of myopericarditis was 33.3 per million vaccine doses, with no significant difference seen for people who received COVID-19 vaccines and those who received non-COVID-19 vaccines (18.2 versus 56.0). The incidence of myopericarditis was significantly higher following smallpox vaccinations (132.1) compared with COVID-19 vaccination, but was not significantly different after influenza versus COVID-19 vaccination (1.3) or in studies reporting on other non-smallpox vaccinations (57.0). For those receiving COVID-19 vaccines, significantly higher incidence of myopericarditis was seen for males versus females, those aged <30 versus \u00e2\u0089\u00a530 years, after a receiving an mRNA versus a non-mRNA vaccine, and after a second versus first or third dose.<\/p>\n “The overall risk of myopericarditis appears to be no different for this newly approved group of vaccines against COVID-19, compared to vaccines against other diseases,” a coauthor said in a statement. “The risk of such rare events should be balanced against the risk of myopericarditis from infection and these findings should bolster public confidence in the safety of COVID-19 vaccinations.”<\/p>\n One author disclosed financial ties to Baxter.<\/p>\n